Rituximab News and Research

RSS

Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.

Turning autoimmunity drugs into anti-cancer treatments

Professor Mark Cragg speaks to News-Medical about his research which involves turning autoimmunity drugs into anti-cancer treatments.

11 Jun 2020

Novel compound shows promise for ANCA-associated vasculitis

ANCA-associated vasculitis (AAV) is a systemic disease involving the formation of special autoantibodies (so-called anti-neutrophil cytoplasmic antibodies/ANCA) and vascular inflammation.

8 Jun 2020

Phase III clinical trial shows benefit of rituximab for pediatric Burkitt lymphoma

Results of the phase III Inter-B-NHL-ritux 2010 clinical trial reported today in the New England Journal of Medicine show 95 percent three-year survival for pediatric patients with advanced B-cell non-Hodgkin lymphoma treated with the addition of anti-cancer immunotherapy rituximab to standard chemotherapy.

3 Jun 2020

Study focuses on COVID-19 patients with inflammatory rheumatic diseases

The ongoing COVID-19 pandemic has caused nearly five million cases and over 327,000 deaths worldwide. The signs and symptoms of this disease are varied, although there are typical features which assist diagnosis.

20 May 2020

Drug combo for untreated CLL approved by FDA based on E1912 trial

Patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma now have a new treatment option--a combination of the targeted agent ibrutinib with the immunologic agent rituximab.

29 Apr 2020

Novel and targeted cellular product causes cell death in non-Hodgkin lymphoma models

Investigators at Rutgers Cancer Institute of New Jersey have found that a treatment based on a novel cellular product programmed to deliver an overabundance of chimeric antigen receptor causes cell death in non-Hodgkin lymphoma models that are sensitive or resistant to standard therapies.

16 Dec 2019

Ibrutinib-based therapy provides superior clinical outcomes in majority of CLL patients

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) today announced results from an extended follow-up analysis of patients in its randomized Phase 3 clinical trial, E1912.

8 Dec 2019

Study: Calcium signaling can help address drug resistance to non-Hodgkin lymphoma

Gene expression profiling and other analyses conducted by Rutgers Cancer Institute of New Jersey researchers and colleagues examining drug resistance to a common antibody therapy for non-Hodgkin lymphoma have identified calcium signaling as a novel and exploitable target in overcoming this treatment obstacle.

3 Dec 2019

Tailored T-cells safe, may be effective in preventing and treating multiple viral infections

Tailored T-cells specially designed to combat a half dozen viruses are safe and may be effective in preventing and treating multiple viral infections, according to research led by Children's National Hospital faculty.

18 Nov 2019

Drug regimen for lymphoma and RA more likely to put patients with pemphigus into remission

Pemphigus, an autoimmune disease mediated by B cells and which causes painful blisters and sores on the skin and mucous membranes, is a rare chronic autoimmune condition that can be fatal if not treated.

11 Nov 2019

Juvenile immune arthritis – new treatments wanted

Juvenile immune arthritis (JIA) is a severely undertreated condition, and new medications are badly needed to relieve the signs and symptoms of the illness, according to a new study presented at the 2019 ACR/ARP Annual Meeting.

11 Nov 2019

Tocilizumab more effective than rituximab in achieving low disease activity in RA patients

New research discovered that tocilizumab is more effective than rituximab in achieving low disease activity in patients with rheumatoid arthritis whose synovial tissue show a low level of B cell infiltration and did not respond to conventional synthetic disease-modifying anti-rheumatic drugs (conventional synthetic DMARDs) or tumor necrosis factor inhibitors first.

11 Nov 2019

Study provides first data on infectious risk in children exposed to non-TNFi biologics and tofacitinib

A new study found that very few serious infections were seen in children born to mothers with chronic inflammatory diseases who used non-TNFi biologics or tofacitinib during pregnancy compared to children not exposed to these drugs and children exposed to TNFi biologics in utero.

10 Nov 2019

Additional medications needed to control the symptoms of juvenile idiopathic arthritis

According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, there is a profound ongoing need for additional medications to control the signs and symptoms of juvenile idiopathic arthritis, despite the availability of several approved biologic disease-modifying antirheumatic drugs (biologics).

10 Nov 2019

New research shows significant gaps in deployment of 'coverage with evidence development'

Value in Health, the official journal of ISPOR- the professional society for health economics and outcomes research, announced today the publication of new research from The Netherlands showing important gaps in the deployment of "coverage with evidence development," a type of pharmaceutical managed entry agreement that gives patients access to treatments while additional evidence is being collected.

15 Jul 2019

First chemoimmunotherapy regimen approved by FDA for patients with diffuse large B-cell lymphoma

Today, the U.S. Food and Drug Administration granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (a combination known as "BR"), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies.

10 Jun 2019

Study reveals investigational drug as effective treatment for relapsed marginal zone lymphoma

A study at The University of Texas MD Anderson Cancer Center revealed the investigational drug umbralisib as an effective treatment for patients with relapsed marginal zone lymphoma.

1 Apr 2019

Researchers find cause, treatment for CVID lung disease using precision medicine

Researchers have identified that dysfunction of a specific immune cell, called B cells, underlies lung disease that affects patients with the rare immunological disorder known as common variable immunodeficiency.

8 Mar 2019

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

The U.S. Food and Drug Administration today approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin's lymphoma (NHL) to be used as a single agent or in combination with chemotherapy.

29 Nov 2018

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.

1 Nov 2018

Rituximab News and Research

Turning autoimmunity drugs into anti-cancer treatments

Novel compound shows promise for ANCA-associated vasculitis

Phase III clinical trial shows benefit of rituximab for pediatric Burkitt lymphoma

Study focuses on COVID-19 patients with inflammatory rheumatic diseases

Drug combo for untreated CLL approved by FDA based on E1912 trial

Novel and targeted cellular product causes cell death in non-Hodgkin lymphoma models

Ibrutinib-based therapy provides superior clinical outcomes in majority of CLL patients

Study: Calcium signaling can help address drug resistance to non-Hodgkin lymphoma

Tailored T-cells safe, may be effective in preventing and treating multiple viral infections

Drug regimen for lymphoma and RA more likely to put patients with pemphigus into remission

Juvenile immune arthritis – new treatments wanted

Tocilizumab more effective than rituximab in achieving low disease activity in RA patients

Study provides first data on infectious risk in children exposed to non-TNFi biologics and tofacitinib

Additional medications needed to control the symptoms of juvenile idiopathic arthritis

New research shows significant gaps in deployment of 'coverage with evidence development'

First chemoimmunotherapy regimen approved by FDA for patients with diffuse large B-cell lymphoma

Study reveals investigational drug as effective treatment for relapsed marginal zone lymphoma

Researchers find cause, treatment for CVID lung disease using precision medicine

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News